Skip to Content

Rixubis Approval History

  • FDA approved: Yes (First approved June 26th, 2013)
  • Brand name: Rixubis
  • Generic name: coagulation factor IX (recombinant)
  • Dosage form: Injection
  • Company: Baxter International Inc.
  • Treatment for: Hemophilia B

Rixubis (coagulation factor IX, recombinant) is an antihemophilic factor indicated for the control and prevention of bleeding episodes in adults with hemophilia B.

Development History and FDA Approval Process for Rixubis

Jun 27, 2013Approval FDA Approves Rixubis - First Recombinant Coagulation Factor IX For Use in Preventing Bleeding Episodes

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.